Citadel Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,800
| Closed | -$75.5K | – | 15770 |
|
|
2024
Q1 | $75.5K | Buy |
4,800
+4,500
| +1,500% | +$69.3K | ﹤0.01% | 11724 |
|
|
2023
Q4 | $4.84K | Sell |
300
-3,400
| -92% | -$43.4K | ﹤0.01% | 13478 |
|
|
2023
Q3 | $47.1K | Buy |
+3,700
| New | +$51K | ﹤0.01% | 11824 |
|
|
2023
Q2 | – | Sell |
-13,900
| Closed | -$215K | – | 15470 |
|
|
2023
Q1 | $215K | Sell |
13,900
-76,600
| -85% | -$1.28M | ﹤0.01% | 10063 |
|
|
2022
Q4 | $1.48M | Sell |
90,500
-4,100
| -4% | -$66.7K | ﹤0.01% | 6055 |
|
|
2022
Q3 | $1.75M | Sell |
94,600
-65,800
| -41% | -$1.03M | ﹤0.01% | 5840 |
|
|
2022
Q2 | $2.11M | Buy |
160,400
+6,000
| +4% | +$66.2K | ﹤0.01% | 5440 |
|
|
2022
Q1 | $1.43M | Sell |
154,400
-163,800
| -51% | -$1.39M | ﹤0.01% | 6850 |
|
|
2021
Q4 | $3.11M | Buy |
318,200
+265,600
| +505% | +$4.99M | ﹤0.01% | 5267 |
|
|
2021
Q3 | $1.79M | Buy |
52,600
+26,900
| +105% | +$859K | ﹤0.01% | 6662 |
|
|
2021
Q2 | $941K | Buy |
25,700
+1,800
| +8% | +$69.7K | ﹤0.01% | 8521 |
|
|
2021
Q1 | $1.07M | Sell |
23,900
-5,300
| -18% | -$247K | ﹤0.01% | 7943 |
|
|
2020
Q4 | $1.67M | Buy |
29,200
+4,000
| +16% | +$237K | ﹤0.01% | 5755 |
|
|
2020
Q3 | $1.29M | Sell |
25,200
-4,400
| -15% | -$216K | ﹤0.01% | 5561 |
|
|
2020
Q2 | $1.77M | Sell |
29,600
-16,900
| -36% | -$904K | ﹤0.01% | 4800 |
|
|
2020
Q1 | $1.91M | Sell |
46,500
-31,100
| -40% | -$1.73M | ﹤0.01% | 4209 |
|
|
2019
Q4 | $4.83M | Buy |
77,600
+28,100
| +57% | +$1.34M | ﹤0.01% | 3126 |
|
|
2019
Q3 | $1.68M | Buy |
+49,500
| New | +$1.47M | ﹤0.01% | 4771 |
|
Other funds holding DCPH
Citadel Advisors's DCPH Position: Q2 2024 in Review
Citadel Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 110,550 shares — an estimated $1.74M sold.
Citadel Advisors first reported a position in DCPH in Q3 2017 and held it in 25 quarters. The position peaked at $17.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Citadel Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 110,550 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.74M.
- Citadel Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 25 quarters.
- Citadel Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.